Announcements Trials
Browse Landscape

Phase

Phase 3 7Phase 2 6Phase 1 5Phase 1/2 4Phase 2/3 2Phase 4 1

Status

Recruiting 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 2

Conditions

Multiple Myeloma 2

Interventions

Cisplatin 22pembrolizumab 17Drug Therapy 16Carboplatin 15Paclitaxel 12Dexamethasone 12Gemcitabine 11Magnetic Resonance Spectroscopy 10Bevacizumab 10Docetaxel 9venetoclax 8atezolizumab 8Pemetrexed 8Oxaliplatin 8Specimen Handling 7Radiotherapy 7Nivolumab 7Cyclophosphamide 7Capecitabine 7Methotrexate 6130-nm albumin-bound paclitaxel 6durvalumab 5blinatumomab 5Cytarabine 5Androgen Antagonists 5tislelizumab 4spartalizumab 4pertuzumab 4Vincristine 4Trimethoprim, Sulfamethoxazole Drug Combination 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2/3 × Recruiting × carfilzomib × Clear all
NCT04513639 2025-03-20

The Relapse from MRD Negativity As Indication for Treatment (REMNANT) Study

Oslo University Hospital

Phase 2/3 Recruiting
176 enrolled
Plasma cell

Multiple Myeloma

NCT06879379 2025-03-17

KPD Consolidation After ASCT in NDMM Patients

Peking University People's Hospital

Phase 2/3 Recruiting
202 enrolled
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡